What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Complete Phasing and Consensus Generation of Genomic Sequences Using Illumina MiSeq NGS Technology

Authors: Szilveszter Juhos, György Horváth, Krisztina Rigó, Jamie Duke, Deborah Ferriola, Tim Hague, Dimitri Monos Introduction: IMGT/HLA 3.19.0 contains 12705 sequences, 11464 of them are partial Sanger can cover only some part of the important exons, NGS can do a whole-gene …more

By kriszta.katona 0 comments

Omixon Celebrates a Successful EFI 2015

EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more

By kriszta.katona 0 comments